BromfenacSodium , 10mMinDMSO , 91714-93-1
Synonym(s):
2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt
CAS NO.：91714-93-1
Empirical Formula: C15H11BrNNaO3
Molecular Weight: 356.15
MDL number: MFCD03701673
EINECS: 804-379-0
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB399.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 285 ºC |
| storage temp. | 2-8°C |
| solubility | H2O: ≥5mg/mL |
| form | powder |
| color | faint yellow to dark yellow |
| InChIKey | HZFGMQJYAFHESD-UHFFFAOYSA-M |
| CAS DataBase Reference | 91714-93-1 |
Description and Uses
Bromfenac Sodium was launched in the US as a potent, orally-active, long lasting peripheral analgesic with antiinflammatory properties. It is structurally similar to ketoprofen and diclofenac and can be prepared in three steps from 2-amino-4’-bromophenone using Gassman’s oxindole synthesis. Duract’s biological effects are a result of its ability to reduce prostaglandin production through inhibition of cyclooxygenase. As a 4-bromo derivative of Amfenac, this modification increased the duration of analgesic activity and antiinflammatory potency. It was also free of any CNS, cardiovascular or autonomic effects. In comparison, 5 mg of Duract was equipotent to 650 mg of ASA and 25 mg was slightly more potent than 400 mg of Ibuprofen.
Bromfenac (Xibrom, ISTA Pharmaceuticals, Irvine, USA; Bronuck, Senju Pharmaceutical, Osaka, Japan) is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients after undergoing cataract extraction. For this task, one drop of Xibrom may be applied to the affected eye twice daily beginning 24 hours after cataract surgery and continuing for the first 2 weeks of the postoperative period. The clinical safety and efficacy of bromfenac have been extensively studied in diverse comparative investigations, including the treatment of external or anterior ocular inflammatory diseases, allergic conjunctivitis, scleritis, and postoperative inflammation.The results of two phase III multicenter, randomized double-masked placebo-controlled clinical trials showed that bromfenac ophthalmic solution 0.09% was effective in the rapid resolution of ocular pain after cataract surgery, and there was a statistically significant difference between the bromfenac and placebo groups demonstrated in these phase III clinical trials.
